Please use this identifier to cite or link to this item:
Title: Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against eph family receptors
Austin Authors: Charmsaz, Sara;Scott, Andrew M ;Boyd, Andrew W
Affiliation: Leukaemia Foundation Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, Australia
Department of Medicine, University of Queensland, Brisbane, Australia
Department of Surgery, Royal College of Surgeons, Dublin, Ireland
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Australia
Department of Medicine, University of Melbourne, Melbourne, Australia
Issue Date: Oct-2017 2017-07-24
Publication information: Experimental Hematology 2017; 54: 31-39
Abstract: The use of monoclonal antibodies and molecules derived from them has achieved considerable attention and success in recent years establishing this mode of therapy as important therapeutic strategy in many cancers and in particular in hematological tumors. Monoclonal antibodies recognize cell surface antigens expressed on target cells and mediate their function through various mechanisms, such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or by modulating the immune system. The efficacy of monoclonal antibody therapy can be improved when conjugates to a highly potent payloads including cytotoxic drugs and radiolabelled isotopes. The Eph family of protein has received considerable attention in recent years as therapeutic targets for treatment of both solid and hematological cancers. High expression of Eph receptors on cancer cells in comparison to low expression levels in normal adult tissues makes them an attractive candidate for cancer immunotherapeutic. In this review we will detail the modes of action of antibody based therapies and will focus on the Eph family of proteins as potential targets for therapy in hematological malignancies.
DOI: 10.1016/j.exphem.2017.07.003
ORCID: 0000-0002-6656-295X
PubMed URL:
Type: Journal Article
Subjects: Cancer
Hematological malignancies
Monoclonal antibody
Therapeutic targeting
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.